Dr. Hsu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
6400 Fannin St
Suite 2800
Houston, TX 77030Phone+1 713-486-8000- Is this information wrong?
Education & Training
- University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1999 - 2001
- New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1996 - 1999
- Yale-New Haven Medical CenterInternship, Internal Medicine, 1995 - 1996
- The Warren Alpert Medical School of Brown UniversityClass of 1995
Certifications & Licensure
- TX State Medical License 2002 - 2024
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
- Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Start of enrollment: 2013 Aug 01
- Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
- Join now to see all
Publications & Presentations
PubMed
- Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.Goldlust, S., Duic, P., Benkers, T., Singer, S., Rao, M., Cappello, L., Silberman, S., Farmer, G., Nabors, L., Hsu, S., Mohile, N.> ;Neuro-Oncology Advances. 2024 Jan 18
- 1 citationsA Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.Colin J Vize, Stella K Kim, Tim Matthews, Marian Macsai, Ryan Merrell, Sigmund Hsu, Madan Gopal Kundu, Jennifer Yoon, Emma Kennedy, Madhavi Pai, Earle Bain, Andrew B L...> ;Ophthalmic Research. 2023 Jan 1
- Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report.Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard, Sigmund Hsu> ;Oncotarget. 2023 May 10
- Join now to see all
Journal Articles
- MRI-Guided Radiotherapy for Head and Neck Cancer: Initial Clinical ExperienceM Cao, S Hsu, Y Yang, M L Steinberg, A M Chen, J Lamb, Clinical & translational oncology
Press Mentions
- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate CommencesOctober 23rd, 2020
Hospital Affiliations
- Memorial Hermann - Texas Medical CenterHouston, Texas
- Memorial Hermann Memorial City Medical CenterHouston, Texas
- TIRR Memorial HermannHouston, Texas
- Memorial Hermann Southwest HospitalHouston, Texas
- Memorial Hermann The Woodlands Medical CenterSpring, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: